21 January 2026
21 January 2026
The agreement covers at least 43 scanners, with an expected revenue exceeding $24m.
Lipocine expects trial data to support a 505(b)(2) new drug application submission for LPCN 1154 in 2026.
Aspect will acquire rights from Novo Nordisk to stem cell-derived islet cell and hypoimmune cell engineering technologies.
Imprivata’s survey found that 85% favour passwordless authentication, yet adoption lags due to technical and integration-related challenges.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
